sar425899 glucagon glp-1 dual agonist sanofi The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Receptor Glucagon-like peptide 1 (GLP-1) -
Description
Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors
Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.
An endocrinologist explains who the pill is right for in the UAE, what the trial numbers actually say, and when the injection still wins.
A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.
SaveHealth reports that Zepbound and Wegovy, both FDA-approved weight loss injectables, differ in mechanisms and efficacy
